KT-621

N/A

Report date: 2026/05/20 20:02:01
NMEFirst In Class

Base Information

Drug NameKT-621
Drug Alias NameKT-621
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSignal transducer and activator of transcription 6 degraders
TargetsSignal transducer and activator of transcription 6
Therapy Area/IndicationsDermatitis, AtopicPeripheral Nervous System DiseasesAlzheimer Disease +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesKymera Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesKymera Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsDermatitis, AtopicPeripheral Nervous System DiseasesAlzheimer Disease +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A